Ordaos

Ordaos Bio: Pioneering AI-driven drug discovery for novel oncology and inflammatory disease therapies.

: 25
: Company
: 2019
: New York, NY, USUnited States

Library

ordaos.bioCrawled Oct 15, 2026

Press

6 pages

Can drug design replace drug discovery? Current JLABS resident Ordaos thinks so and explains how/press/2023/03/09/can-drug-design-replace-drug-discovery-current-jlabs-resident-ordaos-thinks-so-and-explains-how
The page asks about a challenge Ordaōs is trying to solve and says the company seeks to improve the speed and efficiency of an unspecified process.
ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption'/press/2023/08/18/chatgpt-is-just-the-tip-of-the-iceberg-in-content-creating-artificial-intelligence-get-ready-for-a-lot-of-disruption
Artificial intelligence-powered ChatGPT arrived in a firestorm nine weeks ago, wowing the tech world with its ability to do everything from composing a hig
Mini-Proteins Combine Best of Monoclonals and Small-Molecule Drugs/press/2022/10/12/mini-proteins-combine-best-of-monoclonals-and-small-molecule-drugs
The field of mini-proteins is so new that only a handful of research papers have been published about them, but they appear to have the potential to transf
Press/press
Ordaōs in the News

Team

1 page

Team/team

Contact

1 page

Homepage

1 page

Homepage/
ordaos.bio

Privacy

1 page

Coverage

7 items

ordaosbiogithub.com/ordaosbio
GitHubRepository owner
Ordaōs Opens Lab Space in JLABS@NYCordaos.bio/press/2023/08/24/orda%C5%8Ds-opens-lab-space-in-jlabs-nyc
Ordaōs has opened a lab space at JLABS@NYC to accelerate its research and development. The company aims to advance its capabilities in mini-protein drug design, transitioning from computational modeling (*in silico*) to experimental testing (*in vitro*). This move supports Ordaōs’ focus on optimizing its drug development pipeline.
Aug 2023ordaos.bioNews article
Ordaōs Selected to Participate in the AWS Generative AI Acceleratorordaos.bio/press/2023/06/09/orda%C5%8Ds-selected-to-participate-in-the-aws-generative-ai-accelerator
Ordaōs, a drug design company specializing in human-enabled, machine-driven creation of novel mini-proteins, joins the inaugural AWS Generative AI Accelerator cohort. The program provides technical, business, and mentorship support to generative AI startups, aiding Ordaōs in advancing its cloud-native drug discovery solutions for biopharma partners. The company aims to deliver safer, more efficient protein-based therapies through AI-driven design.
Jun 2023ordaos.bioNews article
Ordaōs and FatiAbGen Partner to Optimize Therapeutics for Challenging Oncology Conditionsordaos.bio/press/2023/02/22/orda%C5%8Ds-and-fatiabgen-partner-to-optimize-therapeutics-for-challenging-oncology-conditions
Ordaōs uses AI and machine learning to enhance the safety and efficacy of FatiAbGen’s monoclonal antibodies for oncology treatments. The collaboration aims to accelerate therapeutic development for difficult-to-treat cancer conditions. Both companies focus on leveraging technology to improve drug optimization in precision medicine.
Feb 2023ordaos.bioNews article